Surgical Cardiac Sympathetic Denervation

Uses

Benefits

Risks & contraindications

Comparisons

Evidence quality

Highlighted claims

• Surgical cardiac sympathetic denervation is guideline-endorsed for sudden cardiac death prevention in long QT syndrome and catecholaminergic polymorphic ventricular tachycardia with a recommendation level similar to ICD implantation. — Protocol of the RADIO-STAR trial: a phase 1 safety and dose finding study of hypofractionated radiotherapy to the stellate ganglia for the treatment of ventricular arrhythmia
• In a small randomised trial of myocardial infarction patients with ventricular arrhythmias, sudden cardiac death occurred in 21% of controls versus 3.6% with cardiac sympathetic denervation over 22 months. — Protocol of the RADIO-STAR trial: a phase 1 safety and dose finding study of hypofractionated radiotherapy to the stellate ganglia for the treatment of ventricular arrhythmia
• Bilateral surgical cardiac sympathetic denervation reduces ventricular arrhythmias by more than 60% in patients refractory to all available treatments including maximal beta-blockade. — Protocol of the RADIO-STAR trial: a phase 1 safety and dose finding study of hypofractionated radiotherapy to the stellate ganglia for the treatment of ventricular arrhythmia
• Off-site neurological effects are the most common surgical complication, with altered sensation, temperature regulation, or sweating reported in up to 70% of patients. — Protocol of the RADIO-STAR trial: a phase 1 safety and dose finding study of hypofractionated radiotherapy to the stellate ganglia for the treatment of ventricular arrhythmia
• Bilateral surgical denervation is more effective than left-sided denervation alone. — Protocol of the RADIO-STAR trial: a phase 1 safety and dose finding study of hypofractionated radiotherapy to the stellate ganglia for the treatment of ventricular arrhythmia